CHOOSE CONFIDENCE. SWITCH TO IXINITY.

Offer your patients the confidence that comes with predictable bleed control and flexible dosing.

IXINITY profiles and success stories »

*The pharmacokinetics of IXINITY have been evaluated in 32 previously treated patients ≥12 years of age with severe to moderately severe hemophilia B.

The efficacy (n=68) and safety (n=77) of IXINITY have been evaluated in a prospective, open-label, uncontrolled, multicenter trial in which previously treated patients between 7 and 64 years of age received IXINITY in either a routine or on-demand regimen, including 55 patients with more than 50 exposure days and 45 of those patients with more than 100 exposure days.1

*The pharmacokinetics of IXINITY have been evaluated in 32 previously treated patients ≥12 years of age with severe to moderately severe hemophilia B.

The efficacy (n=68) and safety (n=77) of IXINITY have been evaluated in a prospective, open-label, uncontrolled, multicenter trial in which previously treated patients between 7 and 64 years of age received IXINITY in either a routine or on-demand regimen, including 55 patients with more than 50 exposure days and 45 of those patients with more than 100 exposure days.1

Connect with your local IXINITY Specialist and see if IXINITY is the right treatment for your patients.

Up to 20,000 IU.

Reference 1: IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Aptevo BioTherapeutics LLC; December 2018.